Researchers address diabetes and obesity therapies in Santiago

Researchers address contributions to develop new therapies against diabetes and obesity

More than 50 investigating researchers of the Trans-Ith project participate in Santiago de Compostela in a meeting held from Monday until April 26 in Santiago de Compostela to address "important advances" in the use of nanotechnology for the development of newOral therapies of interest in the treatment of diabetes, obesity and other palotologies.

As reported by the European Trans-Tint consortium, this project has aimed at the integral study of the interaction of certain nanomaterials with the gastro-central tract, after its oral administration.

This study, as indicated, has allowed to evaluate the potential of these nanomaterials such as therapeutic biomolecules, peptides and proteins through the intestinal mucosa.

The advances achieved allow, as they have revealed by the consortium, "to design therapeutic strategies that could be of interest in the systemic treatment of diseases such as diabetes, obesity or pain, as well as the local treatment of inflammatory intestinal diseases".

All these achievements are addressed at the final meeting of the Trans-Tint Consortium, which is held in Santiago de Compostela from this Wednesday with the participation of more than 50 investigators members of the project, as well as representatives of the European Commission.

First session

The meeting has counted during its first session held on Monday morning with the participation of Dr. Justin Hanes of the Johns Hopkins University (USA) and Dr. Felipe Casanueva of the University Hospital of Santiago (Chus), as invited speakers.

The Trans -int project began in 2012 and during its five years it has mobilized almost 11 million euros, of which a large part has been funded by the European Commission through its' Nanosciences, Nanotechnologies, Materials andNew Production Technologies- NMP (NMP.2011.1.2-2 New Targeted Therapy Using Nanotechnology for Transport of Macro-Molecules Across Biological Bariers', of the 7th Frame Program of the CE.

   0